Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05786430 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

Study acronym: LUCAS
StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 5 more changesShow less
    • Final enrollment: 65 participants (planned 87)
    • Primary and study completion dates changed from estimate of Aug 2026 to Aug 23, 2026
    • Interventions: Lazertinib/Pemetrexed/Carboplatin (Drug) to Lazertinib/Pemetrexed/Carboplatin (Drug)
    • Secondary endpoints: details revised at 5 of 5 entries
    • Eligibility criteria shortened, about 1 word
  2. Primary completion date: Dec 2024 to Aug 2026v2 Show 4 more changesShow less
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study completion date: Dec 2025 to Aug 2026
    • Start date changed from estimate of Mar 2023 to Apr 7, 2023
    • Site contact updated
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial is Phase II Trial of Lazertinib+Pemetrexed/Carboplatin in Patients with EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to prior lazertinib.
Trial Details
NCT Number NCT05786430
Lead Sponsor Yonsei University
Conditions
(from sponsor)		 Non-small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 65 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov